lymphoma CTCL

Related by string. * lymphomas . Lymphomas . LYMPHOMA . Lymphoma : cure leukemia lymphoma . Cure leukemia lymphoma . Hodgkin lymphoma HL . leukemia lymphoma . Mantle Cell Lymphoma . Non Hodgkin Lymphoma . Non Hodgkin lymphoma . refractory Hodgkin lymphoma . non Hodgkins lymphoma . non Hodgkin lymphoma / Ct. Cl : cell lymphoma CTCL . refractory CTCL . CTCL * Cell Lymphoma CTCL *

Related by context. All words. (Click for frequent words.) 85 cutaneous T cell 79 cell lymphoma CTCL 76 cutaneous T 72 refractory acute myeloid 70 recurrent NSCLC 70 romidepsin 70 relapsed refractory multiple myeloma 70 refractory chronic lymphocytic 70 leukemia AML 70 systemic anaplastic large 69 phase IIb clinical 69 metastatic renal cell carcinoma 69 leukemia CLL 69 refractory cutaneous T 69 Cutaneous T 69 Romidepsin 69 hormone refractory prostate cancer 68 dasatinib Sprycel ® 68 refractory Hodgkin lymphoma 68 relapsed multiple myeloma 68 PNP inhibitor 68 myelofibrosis 68 mRCC 68 IV metastatic melanoma 68 B CLL 68 alvespimycin 68 recurrent glioblastoma multiforme 68 multiple myeloma MM 68 HER2 positive metastatic breast 68 Brentuximab Vedotin SGN 67 non metastatic osteosarcoma 67 advanced metastatic renal 67 lintuzumab SGN 67 CYT# potent vascular disrupting 67 refractory multiple myeloma 66 relapsing remitting multiple sclerosis 66 castration resistant prostate cancer 66 Aflibercept 66 metastatic malignant melanoma 66 castrate resistant prostate cancer 66 sorafenib tablets 66 docetaxel Taxotere ® 66 chronic lymphocytic leukemia CLL 66 R sorafenib tablets 66 refractory CTCL 66 metastatic colorectal cancer 66 tumors GIST 66 gastrointestinal stromal tumors 66 myelodysplastic syndrome MDS 66 indolent NHL 66 refractory indolent non 66 metastatic colorectal 66 Hodgkin lymphoma NHL 66 oral ridaforolimus 66 unresectable 66 gastrointestinal stromal tumor GIST 66 non squamous 66 Amrubicin 66 metastatic castration resistant 66 hypereosinophilic syndrome 66 cetuximab Erbitux R 65 stage IIIB 65 previously untreated follicular 65 unresectable locally advanced 65 refractory NSCLC 65 forodesine HCl 65 acute myelogenous leukemia AML 65 metastatic GIST 65 heavily pretreated 65 vandetanib 65 unresectable stage 65 Phase #b/#a clinical 65 relapsing remitting MS RRMS 65 metastatic pancreatic 65 Acute Myeloid Leukemia AML 65 IV NSCLC 65 Hsp# Inhibitor 65 metastatic renal cell 65 opioid induced constipation OIC 65 axitinib 65 mapatumumab 65 indolent follicular non 65 systemic ALCL 65 PEGylated interferon beta 1a 65 HGS ETR2 65 ponatinib 65 erlotinib Tarceva ® 65 recurrent GBM 65 hepatocellular carcinoma HCC 65 generation purine nucleoside 65 unique alkylating agent 65 prostate cancer CRPC 65 relapsed SCLC 64 atypical Hemolytic Uremic Syndrome 64 lumiliximab 64 refractory peripheral T 64 metastatic CRC 64 hepatitis C HCV 64 chronic plaque psoriasis 64 chronic myeloid leukemia CML 64 receptor tyrosine kinase inhibitor 64 Golimumab 64 Genasense ® 64 IL# PE#QQR 64 glufosfamide 64 Epratuzumab 64 cell carcinoma RCC 64 ZYBRESTAT 64 huN# DM1 64 FOLOTYN ® 64 registrational trial 64 Cloretazine 64 myelofibrosis polycythemia vera 64 severe hypercholesterolemia 64 leukemia APL 64 essential thrombocythemia ET 64 NSCLC 64 mTOR inhibitor 64 Myelodysplastic Syndrome MDS 64 Romiplostim 64 stage IIIb IV 64 rALLy clinical trial 64 familial amyloidotic polyneuropathy FAP 64 Hodgkin lymphoma HL 64 leukemia ALL 64 metastatic hormone refractory 64 forodesine 64 Diabetic Macular Edema 64 nilotinib 64 CTCL 64 Ceflatonin 64 Proxinium TM 64 MAGE A3 ASCI 64 gastrointestinal stromal tumors GIST 64 HRPC 64 BCG refractory carcinoma 63 hormone refractory metastatic prostate 63 MyVax R 63 PDX pralatrexate 63 chronic myeloid 63 metastatic melanoma 63 imatinib resistant 63 Kit CD# positive 63 pseudobulbar affect PBA 63 hematologic malignancies 63 Vicinium TM 63 novel histone deacetylase 63 AVASTIN 63 VEGFR2 inhibitor 63 idiopathic pulmonary fibrosis IPF 63 docetaxel Taxotere R 63 refractory colorectal cancer 63 superficial bladder cancer 63 antibody MAb 63 vismodegib 63 IMA# 63 renal cell carcinoma 63 chronic angina 63 lupus nephritis 63 Alemtuzumab 63 medullary thyroid cancer 63 R lenalidomide 63 sorafenib Nexavar 63 BRIM2 63 Pivotal Phase III 63 mCRC 63 phase IIb trial 63 RSR# 63 anthracycline taxane 63 INSPIRE Trial Phase III 63 eltrombopag 63 TORISEL 63 evaluating tivozanib 63 Azedra 63 OMP #R# 63 OMNARIS HFA 63 recurrent glioma 63 galiximab 63 hematological malignancies 63 riociguat 63 Xanafide 63 myelodysplastic myeloproliferative diseases 63 acute GvHD 63 relapsed leukemia 63 KRN# 63 nab paclitaxel 63 HGS ETR1 63 anthracyclines taxanes 63 glioblastoma multiforme GBM 63 myelodysplastic syndromes MDS 63 CEQ# 63 Hepatocellular Carcinoma HCC 63 Cimzia TM 63 lymphoid malignancies 63 huC# DM4 63 refractory AML 63 temsirolimus 63 primary hypercholesterolemia 63 relapsed refractory 63 T Cell Lymphoma 63 essential thrombocythemia 63 dirucotide MBP# 63 plus gemcitabine 63 advanced NSCLC 63 refractory CLL 63 metastatic RCC 63 metastatic castrate resistant 63 T#I mutation 63 vemurafenib 63 cancer mCRC 63 cetuximab Erbitux ® 63 VELCADE melphalan 63 EGFR expressing 63 superficial basal cell carcinoma 63 Diffuse Large B 63 Tarceva TM 63 Annamycin 63 papillary renal cell carcinoma 62 ribavirin RBV 62 hepatocellular cancer 62 Zenvia ™ 62 rALLy 62 nilotinib Tasigna ® 62 chronic eosinophilic leukemia 62 metastatic gastric 62 Fludara ® 62 carboplatin paclitaxel 62 aflibercept VEGF Trap 62 Pivotal Trial 62 dependent kinase inhibitor 62 post herpetic neuralgia PHN 62 histone deacetylase HDAC inhibitor 62 YONDELIS 62 ELACYT 62 relapsed MM 62 #I TM# 62 SCH # 62 imatinib mesylate 62 pralatrexate 62 demonstrated antitumor activity 62 Myelofibrosis 62 EGFR expressing mCRC 62 OncoVEX GM CSF 62 unresectable recurrent 62 dasatinib Sprycel 62 Phase #/#a trial 62 Omacetaxine 62 investigational monoclonal antibody 62 multiple myeloma 62 relapsing multiple sclerosis 62 ACTEMRA TM 62 Evoltra ® 62 myelofibrosis MF 62 HBeAg negative 62 severe oral mucositis 62 virus HCV protease inhibitor 62 alfa 2a 62 platinum refractory 62 mitoxantrone plus 62 recurrent glioblastoma 62 Zenvia TM 62 PXD# 62 ZOLINZA 62 PANVAC VF 62 rheumatoid arthritis psoriatic arthritis 62 registrational 62 tanespimycin 62 phase IIa clinical 62 imatinib therapy 62 dirucotide 62 sapacitabine 62 Methylnaltrexone 62 mCRC patients 62 catheter occlusion 62 Acute Myelogenous Leukemia AML 62 MGd 62 minimally symptomatic 62 zalutumumab 62 BAY #-# 62 metastatic bladder 62 Acute Myeloid Leukemia 62 unresectable malignant mesothelioma UMM 62 Onalta ™ 62 ADVEXIN 62 remission induction 62 ILUVIEN ® 62 MKC# MT 62 AA Amyloidosis 62 IV melanoma 62 situ CIS 62 TYZEKA 62 orally administered inhibitor 62 purpura ITP 62 recurrent malignant glioma 62 ISTODAX ® 62 imatinib Gleevec ® 62 unresectable tumors 62 forodesine hydrochloride 62 bevacizumab Avastin ® 62 relapsed Acute Myeloid 62 PEGylated anti 62 Sudhir Agrawal D.Phil 62 Li Fraumeni Syndrome 62 relapsed GBM 62 Cannabinor 62 RG# [001] 62 AA amyloidosis 62 interferon gamma 1b 62 chlorambucil 62 AP# [003] 62 subcutaneous formulation 62 EOquin TM 62 Hedgehog Pathway Inhibitor 62 Torisel 62 metastatic malignant 62 docetaxel chemotherapy 62 phase IIb study 62 refractory APL 62 Metastatic Melanoma 62 metastatic HRPC 62 monoclonal antibody conjugated 62 TELINTRA 62 R roscovitine CDK cyclin 62 Allovectin 7 ® 62 Phase IIIb clinical 62 myeloproliferative disorders 62 TACI Ig 62 Cell Lymphoma 61 metaglidasen 61 hematological cancers 61 IgG1 monoclonal antibody 61 radiation sensitizer 61 Dacogen injection 61 dacarbazine DTIC 61 HuMax CD4 61 Amigal 61 CTAP# Capsules 61 TREANDA 61 keloid scarring 61 cell lymphoma PTCL 61 ruxolitinib 61 thymalfasin 61 diabetic neuropathic pain 61 IBS C 61 Clolar 61 FOLFOX6 61 Voreloxin 61 Cloretazine ® 61 Relapsed Refractory 61 pediatric malignancies 61 primary immunodeficiency PI 61 induced macular edema 61 solid tumors 61 ISTODAX 61 Ofatumumab 61 esophageal candidiasis 61 Soliris TM eculizumab 61 Azixa 61 advanced carcinoid 61 R vitespen 61 prostate cancer HRPC 61 ixabepilone 61 CML CP 61 EGFR expressing metastatic colorectal 61 idiopathic thrombocytopenic purpura ITP 61 autologous cellular immunotherapy 61 myelodysplastic syndromes 61 Campath ® 61 depsipeptide 61 de novo kidney transplant 61 FOLFOX6 chemotherapy regimen 61 Pralatrexate 61 Solazed TM 61 elotuzumab 61 ADVEXIN p# therapy 61 fallopian tube cancers 61 metastatic carcinoid 61 T#I [002] 61 Clevudine 61 dextromethorphan quinidine 61 briakinumab 61 Pegasys ® 61 Chronic Myeloid Leukemia 61 ThermoDox ® 61 refractory metastatic 61 irinotecan containing 61 Traficet EN 61 BARACLUDE ® 61 gemcitabine Gemzar ® 61 imatinib Gleevec 61 BRAF inhibitor 61 Pemetrexed 61 acute myeloid 61 HBeAg positive patients 61 refractory gout 61 systemic fungal infections 61 PROVENGE ® 61 targeted radiotherapeutic 61 Nexavar ® 61 BENLYSTA belimumab 61 Chemophase 61 Phase 2b clinical 61 metastatic ocular 61 multi kinase inhibitor 61 hypercalcemia 61 PEGINTRON TM 61 Sapacitabine 61 Peginterferon alfa 2b 61 Solazed ™ 61 refractory myeloma 61 ocular formulation 61 elacytarabine 61 secondary hyperparathyroidism 61 chronic ITP patients 61 Advanced Renal Cell 61 Ozarelix 61 evaluating picoplatin 61 Chronic Myeloid Leukemia CML 61 CR# vcMMAE 61 neurogenic orthostatic hypotension 61 ThermoDox R 61 immune idiopathic thrombocytopenic 61 pancreatic neuroendocrine tumors 61 Glioblastoma Multiforme 61 systemic lupus erythematosus 61 haematologic malignancies 61 LymphoStat B 61 Combination REOLYSIN R 61 Personalized Immunotherapy 61 dacarbazine 61 virus HCV infection 61 CIMZIA TM certolizumab pegol 61 diabetic gastroparesis 61 ALN TTR 61 gastrointestinal stromal tumor 61 Relapsing Remitting Multiple Sclerosis 61 Oral Fingolimod 61 adalimumab Humira 61 unstable angina UA 61 Chronic Lymphocytic Leukemia 61 modified glutathione analog 61 atherothrombotic events 61 prostate cancer mCRPC 61 sunitinib Sutent 61 acute myeloid leukemia AML 61 oral prodrug 61 confirmatory Phase III 61 Seliciclib 61 refractory metastatic colorectal cancer 61 metastatic colorectal carcinoma 61 Lupus Nephritis 61 pancreatic carcinoma 61 Ophena TM 61 eculizumab 61 Lenocta TM 61 resistant ovarian cancer 61 NYHA Class II 61 oral deforolimus 61 pain palliation 61 LEUKINE 61 mertansine 61 alefacept 61 novel VDA molecule 61 RRMS 61 acute promyelocytic leukemia APL 61 systemic lupus erythematosus SLE 61 Myelodysplastic Syndrome 61 assessing T DM1 61 KIACTA ™ 61 refractory PTCL 61 Rituxan rituximab 61 HP Acthar Gel repository 61 androgen independent 61 Doxil ® 61 Taxotere R 61 hyperphenylalaninemia HPA due 61 invasive candidiasis 61 resistant hormone refractory 61 baminercept 60 Virulizin ® 60 Syndrome LEMS 60 Aryplase 60 Daclizumab 60 pediatric Crohn disease 60 chronic myelogenous leukemia CML 60 plus prednisone 60 SNT-MC#/idebenone 60 eosinophilic asthma 60 Folotyn 60 gefitinib Iressa 60 trabectedin 60 noninfectious uveitis 60 neratinib 60 diarrhea predominant irritable 60 FOLOTYN 60 metastatic CRPC 60 Application MAA 60 tyrosine kinase inhibitor TKI 60 Zolinza 60 non squamous NSCLC 60 HQK 60 ospemifene 60 Fludara 60 TO AVOID PREGNANCY WHILE 60 SAR# [004] 60 Phase 2b Clinical Trial 60 oral methylnaltrexone 60 Nexavar sorafenib 60 octreotide implant 60 Onrigin 60 Metastatic Colorectal Cancer 60 taxane chemotherapy 60 hepatocellular carcinoma 60 Phenoptin 60 Pirfenidone 60 Forodesine HCl 60 Major Depressive Disorder MDD 60 arthritis PsA 60 investigational therapies 60 pomalidomide 60 ganetespib 60 refractory acute promyelocytic 60 COPEGUS ribavirin 60 EOquin 60 basal cell carcinoma BCC 60 bardoxolone methyl 60 mitogen activated ERK kinase 60 carcinoid syndrome 60 rituximab refractory 60 Sezary syndrome 60 Meets Primary Endpoint 60 small lymphocytic lymphoma 60 PRT# 60 Lenocta 60 Vidaza azacitidine 60 TNF antagonist 60 IRESSA 60 Fibrillex TM 60 sunitinib malate 60 MT# MEDI 60 neuroendocrine tumors 60 Gleevec resistant 60 cyclophosphamide chemotherapy 60 Tyrima 60 dasatinib 60 aHUS 60 irinotecan chemotherapy 60 invasive aspergillosis 60 pegylated interferon alfa 2a 60 ara C 60 SPRYCEL ® 60 BENLYSTA ® 60 AAG geldanamycin analog 60 IMiDs 60 Bezielle 60 angiogenesis inhibitor 60 INCB# [001] 60 metastatic NSCLC 60 follicular Non Hodgkin 60 Nimotuzumab 60 fallopian tube carcinoma 60 follicular lymphoma FL 60 Behcet uveitis 60 MYLOTARG 60 epithelial tumors 60 Darinaparsin 60 Apaziquone 60 PREZISTA r 60 unresectable Stage III 60 TTF Therapy 60 formerly LymphoStat B 60 Phase Ib IIa 60 non metastatic resectable 60 thalidomide Thalomid 60 REMICADE ® 60 vinca alkaloid 60 alpha folate receptor 60 carcinoma mCRC 60 oral Azacitidine 60 MEND CABG II 60 crizotinib PF # 60 ZYBRESTAT fosbretabulin 60 talactoferrin 60 cetuximab Erbitux 60 Eculizumab 60 ZACTIMA 60 PEG SN# 60 posaconazole 60 pegylated interferon alpha 60 generation Hsp# inhibitor 60 Pegloticase 60 trastuzumab Herceptin ® 60 supplemental Biologics License Application 60 Clolar ® 60 hereditary deficiency 60 bortezomib Velcade R 60 Plicera 60 non resectable 60 Acute myeloid leukemia AML 60 Enzastaurin 60 atypical hemolytic uremic syndrome 60 advanced unresectable 60 eritoran 60 tumor lysis syndrome 60 ALN HPN 60 biologic therapy 60 UPLYSO 60 visilizumab 60 LymphoStat B belimumab 60 kidney urologic 60 metastatic carcinoma 60 tafamidis 60 pancreatic adenocarcinoma 60 lenalidomide Revlimid R 60 Pegasys plus Copegus 60 TG# [003] 60 5 FU leucovorin 60 fosbretabulin 60 non myeloid malignancies 60 JAK inhibitor 60 ongoing Phase 1b 60 stable angina pectoris 60 Tarceva erlotinib 60 Gleevec imatinib 60 differentiated thyroid 60 dose escalation clinical 60 Evoltra TM 60 INCB# [002] 60 severe neutropenia 60 oropharyngeal candidiasis OPC 60 proteasome inhibitor 60 Acute myeloid leukemia 60 IMGN# 60 MYDICAR ® 60 palifermin 60 oropharyngeal candidiasis 60 INCB# [003] 60 interferon alfa 2a 60 advanced hepatocellular carcinoma 60 Initiates Enrollment 60 Albuferon TM 60 Alzhemed TM 60 Palifosfamide 60 intravenous belinostat 60 Iluvien ® 60 toenail onychomycosis 60 pediatric acute lymphoblastic 60 Philadelphia Chromosome Positive 60 LymphoStat B TM 60 liver metastases 60 diagnosed multiple myeloma 60 chronic thromboembolic pulmonary 60 luteinizing hormone releasing 60 peritumoral brain edema 60 estramustine 60 phase IIa 59 Herceptin trastuzumab 59 vascular disrupting agent 59 DU #b 59 evaluable 59 non splenectomized 59 rheumatoid arthritis RA psoriatic 59 Ribavirin causes 59 belinostat 59 unresectable liver cancer 59 polycythemia vera PV 59 recurrent metastatic ovarian cancer 59 metastatic renal 59 cell chronic lymphocytic 59 IAP inhibitor 59 Belimumab 59 ribavirin therapy 59 metastatic squamous cell carcinoma 59 acute leukemias 59 BiovaxID TM 59 panitumumab Vectibix 59 symptomatic BPH 59 Aclidinium 59 recurrent squamous cell carcinoma 59 selective modulator 59 CIMZIA TM 59 Tamibarotene 59 post operative ileus 59 Fludarabine 59 Chronic Myelogenous Leukemia CML 59 hyperplasia BPH 59 receiving immunosuppressive therapy 59 IRX 2 59 histologically confirmed 59 Pixantrone 59 TEMODAL 59 trastuzumab Herceptin R 59 R rilonacept Injection 59 Phase 2a trial 59 GATTEX ® 59 Chronic Idiopathic Constipation 59 Etanercept 59 OvaRex ® MAb 59 atrial fibrillation budiodarone ATI 59 psoriatic arthritis PsA 59 ® lenalidomide 59 PKC# 59 Phase IIa clinical 59 CA4P 59 Phase Ib study 59 octreotide 59 XL# XL# 59 5 fluorouracil leucovorin 59 smoldering multiple myeloma 59 constipation OIC 59 homozygous familial hypercholesterolemia 59 LHRH receptor positive 59 GAMMAGARD 59 Relapsed 59 OPAXIO 59 rilonacept 59 Insegia 59 EFAPROXYN 59 HuMax EGFr 59 docetaxel Injection Concentrate 59 completely resected 59 Gel repository corticotropin injection 59 Phase 2a clinical 59 cediranib 59 tamibarotene 59 Actemra tocilizumab 59 HGS ETR1 mapatumumab 59 sapropterin dihydrochloride Tablets 59 Sprycel dasatinib 59 capecitabine Xeloda R 59 metastatic neuroendocrine tumors 59 pan HDAC inhibitor 59 Allovectin 7 59 intravesical infusion therapy 59 thymoma 59 subependymal giant cell 59 chronic lymphocytic leukemia 59 lintuzumab 59 XL# anticancer compounds 59 Pharmacokinetics PK 59 obatoclax 59 biliary tract cancer 59 adjuvant GIST 59 painful diabetic neuropathy 59 delivers fluocinolone acetonide FA 59 Gliadel Wafer 59 zanolimumab 59 severe hypersensitivity reactions 59 plus COPEGUS 59 Tanespimycin 59 stage IIIB IV 59 cinacalcet HCl 59 gastrointestinal mucositis 59 R sipuleucel T 59 relapsed ovarian cancer 59 T DM1 59 Previously Treated 59 Phase Ib clinical 59 Orphan Drug designations 59 posterior uveitis 59 K ras mutations 59 investigational humanized monoclonal antibody 59 Cimzia ® 59 metastatic androgen independent 59 Vidaza R 59 active ankylosing spondylitis 59 Zevalin R Ibritumomab 59 JAK2 inhibitor 59 follicular NHL 59 Pivotal Phase 59 Aviptadil 59 Allovectin 7 R 59 Dapagliflozin 59 leukemia CML 59 transplantation HSCT 59 sunitinib 59 Campath alemtuzumab 59 Octreolin 59 hematologic disorders 59 prGCD 59 Cell Lung Cancer 59 alkylating agent 59 CLARITY study 59 Ocrelizumab 59 Bortezomib 59 Trofex 59 pertuzumab 59 DAVANAT 59 Telavancin 59 amrubicin 59 pancreatic NET 59 Tasimelteon 59 either acutely decompensated 59 multicenter Phase III 59 Everolimus 59 cisplatin chemotherapy 59 Marketing Authorization Application MAA 59 Troxatyl 59 phase Ib 59 tivozanib 59 R Saizen R 59 Safinamide 59 dacetuzumab 59 Zerenex 59 TELCYTA 59 steroid refractory GvHD 59 Application BLA 59 mycosis fungoides 59 Entereg R 59 PEGylated Fab fragment 59 Wafer polifeprosan 59 ON #.Na 59 dexanabinol 59 prospectively defined 59 stage IIIb 59 sorafenib Nexavar ® 59 Laquinimod 59 Quinamed 59 phase III isavuconazole 59 myelodysplastic syndrome 59 HeFH 59 CLL SLL 59 relapsed CLL 59 AEG# 59 cancer neuroendocrine tumor 59 Dasatinib 59 pegylated interferon peg IFN 59 colorectal liver metastases 59 Diabetic Macular Edema DME 59 Lubiprostone 59 humanised monoclonal antibody 59 dihydrochloride Tablets 59 chronic idiopathic thrombocytopenic purpura 59 orally inhaled migraine 59 Anti VEGF 59 docetaxel Taxotere 59 AGILECT R 59 lorvotuzumab mertansine 59 cognitive impairment associated 59 idarubicin 59 SNT MC# 59 nonsmall cell lung cancer 59 BR.# 59 myeloid metaplasia 59 Friedreich Ataxia FRDA 59 vinorelbine 59 Tavocept 59 initiate Phase 1b 59 follicular lymphoma 59 generation PNP inhibitor 59 non hodgkin lymphoma 59 vapreotide acetate 59 SCCHN 59 RSD# oral 59 Dementia Related Psychosis 59 Refractory Peripheral T 59 Tasigna nilotinib 59 azacitidine 59 autoantibody positive 59 Reolysin 59 Phase III Trial 59 lung pancreatic 59 BRIM3 59 gemcitabine chemotherapy 59 RRMS patients 59 Aplidin 59 steroid refractory 59 Panzem R NCD 59 metastatic dermatofibrosarcoma protuberans DFSP 59 FUSILEV enhances 59 AQ4N 59 ALN PCS 59 Archexin 59 immunotherapeutic agent 59 cutaneous melanoma 59 relapsing MS 59 Oracea TM 59 Talabostat 59 valopicitabine 59 NP2 Enkephalin 59 refractory chronic myeloid 59 maribavir 59 CD# CEA 59 Initiate Phase 59 hormone refractory 59 class mGluR5 inhibitor 59 oral nucleoside analogue 59 L MTP PE 59 PI3K/Akt pathway inhibitor 59 hypercholesterolemic patients 59 pediatric glioma 59 APOPTONE 59 Degarelix 59 PROSTVAC TM 59 CINTREDEKIN BESUDOTOX 59 HER2 positive metastatic 59 ofatumumab 59 metastatic sarcomas 59 plus prednisone prednisolone 59 investigational compound 58 LHRH antagonists 58 hypoxia activated prodrug 58 chimeric monoclonal antibody 58 fluoropyrimidine 58 Initiates Phase II 58 plus dexamethasone 58 Glioblastoma Multiforme GBM 58 GVAX ® 58 Ambrisentan 58 Phase IIa trial 58 CCR9 antagonist 58 evaluating T DM1 58 fingolimod 58 Curaxin CBLC# 58 voreloxin 58 M2 subunit 58 acyclovir Lauriad R 58 polycythemia vera essential thrombocythemia 58 IMiDs ® 58 synthetic retinoid 58 Xcellerated T Cells 58 neuroendocrine cancers 58 recurrent metastatic 58 bendamustine 58 chronic HCV 58 acetonide FA 58 chemotherapy induced neutropenia 58 Glufosfamide 58 malignant pleural mesothelioma 58 dose escalation phase 58 soft tissue sarcomas 58 GW# [003] 58 cytokine refractory 58 refractory prostate cancer 58 Fx #A 58 IIa trial 58 Cell Lymphoma CTCL 58 small molecule Hedgehog 58 paclitaxel cisplatin 58 IMPDH inhibitor 58 monotherapy 58 mild vasodilator 58 TTR amyloidosis 58 neoadjuvant therapy 58 efalizumab 58 Triapine 58 Complicated Skin 58 Irinotecan 58 allogeneic bone marrow 58 nucleoside analog 58 highly purified pasteurized 58 follicular non 58 OvaRex R 58 myeloproliferative diseases 58 sunitinib Sutent ® 58 acute HAE attacks 58 sarcoma melanoma 58 samalizumab 58 Phase IIb Trial 58 Pivotal Clinical Trial 58 systemic juvenile idiopathic 58 CD3 monoclonal antibody 58 Revlimid lenalidomide 58 Apoptone 58 ADP receptor antagonist 58 Taxotere ® 58 Neuvenge 58 EGFR inhibitors 58 Randomized Phase II 58 mixed dyslipidemia 58 Fast Track designation 58 hematological malignancy 58 mGluR5 NAM 58 weekly subcutaneous injections 58 treatment naïve genotype 58 Elotuzumab 58 Bevacizumab 58 OMP #M# 58 Exelixis XL# 58 BRAF V# mutation 58 Vandetanib 58 blinatumomab 58 Adalimumab 58 sapropterin dihydrochloride 58 Panzem R 58 Initiate Clinical Trial 58 HERCEPTIN 58 evaluating REVLIMID 58 erythematosus 58 taxane refractory 58 sBLA 58 Sebivo 58 NEUVENGE 58 ZEVALIN 58 AIR CF1 58 Vidaza ® 58 neovascular diseases 58 HCV SPRINT 58 TYKERB

Back to home page